335 related articles for article (PubMed ID: 31242947)
1. Inflammasome inhibitors: promising therapeutic approaches against cancer.
Xu S; Li X; Liu Y; Xia Y; Chang R; Zhang C
J Hematol Oncol; 2019 Jun; 12(1):64. PubMed ID: 31242947
[TBL] [Abstract][Full Text] [Related]
2. Current status of inflammasome blockers as anti-inflammatory drugs.
López-Castejón G; Pelegrín P
Expert Opin Investig Drugs; 2012 Jul; 21(7):995-1007. PubMed ID: 22612568
[TBL] [Abstract][Full Text] [Related]
3. Inflammasome, inflammation and cancer: an interrelated pathobiological triad.
Müzes G; Sipos F
Curr Drug Targets; 2015; 16(3):249-57. PubMed ID: 25547909
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting the Inflammasome: A Chemical Perspective.
Baldwin AG; Brough D; Freeman S
J Med Chem; 2016 Mar; 59(5):1691-710. PubMed ID: 26422006
[TBL] [Abstract][Full Text] [Related]
5. The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases.
Jiang H; Gong T; Zhou R
Adv Immunol; 2020; 145():55-93. PubMed ID: 32081200
[TBL] [Abstract][Full Text] [Related]
6. Current status of terpenoids as inflammasome inhibitors.
Hortelano S; González-Cofrade L; Cuadrado I; de Las Heras B
Biochem Pharmacol; 2020 Feb; 172():113739. PubMed ID: 31786260
[TBL] [Abstract][Full Text] [Related]
7. Inflammasomes: Emerging Central Players in Cancer Immunology and Immunotherapy.
Karan D
Front Immunol; 2018; 9():3028. PubMed ID: 30631327
[TBL] [Abstract][Full Text] [Related]
8. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.
Martínez GJ; Celermajer DS; Patel S
Atherosclerosis; 2018 Feb; 269():262-271. PubMed ID: 29352570
[TBL] [Abstract][Full Text] [Related]
9. NLRP3 Inflammasome: A Possible Link Between Obesity-Associated Low-Grade Chronic Inflammation and Colorectal Cancer Development.
Ahechu P; Zozaya G; Martí P; Hernández-Lizoáin JL; Baixauli J; Unamuno X; Frühbeck G; Catalán V
Front Immunol; 2018; 9():2918. PubMed ID: 30619282
[TBL] [Abstract][Full Text] [Related]
10. Inflammasomes and Cancer.
Karki R; Man SM; Kanneganti TD
Cancer Immunol Res; 2017 Feb; 5(2):94-99. PubMed ID: 28093447
[TBL] [Abstract][Full Text] [Related]
11. Inflammasomes in Inflammation-Induced Cancer.
Lin C; Zhang J
Front Immunol; 2017; 8():271. PubMed ID: 28360909
[TBL] [Abstract][Full Text] [Related]
12. NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent Patents.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2018; 13(1):106-117. PubMed ID: 29076433
[TBL] [Abstract][Full Text] [Related]
13. Ameliorative effects of echinacoside against spinal cord injury via inhibiting NLRP3 inflammasome signaling pathway.
Gao S; Xu T; Guo H; Deng Q; Xun C; Liang W; Sheng W
Life Sci; 2019 Nov; 237():116978. PubMed ID: 31644893
[TBL] [Abstract][Full Text] [Related]
14. NLRP3 inflammasome activation promotes inflammation-induced carcinogenesis in head and neck squamous cell carcinoma.
Huang CF; Chen L; Li YC; Wu L; Yu GT; Zhang WF; Sun ZJ
J Exp Clin Cancer Res; 2017 Sep; 36(1):116. PubMed ID: 28865486
[TBL] [Abstract][Full Text] [Related]
15. Inflammasomes, the eye and anti-inflammasome therapy.
Yerramothu P; Vijay AK; Willcox MDP
Eye (Lond); 2018 Mar; 32(3):491-505. PubMed ID: 29171506
[TBL] [Abstract][Full Text] [Related]
16. Targeting NLRP3 Inflammasome in Inflammatory Bowel Disease: Putting out the Fire of Inflammation.
Shao BZ; Wang SL; Pan P; Yao J; Wu K; Li ZS; Bai Y; Linghu EQ
Inflammation; 2019 Aug; 42(4):1147-1159. PubMed ID: 30937839
[TBL] [Abstract][Full Text] [Related]
17. Inflammasomes in carcinogenesis and anticancer immune responses.
Zitvogel L; Kepp O; Galluzzi L; Kroemer G
Nat Immunol; 2012 Mar; 13(4):343-51. PubMed ID: 22430787
[TBL] [Abstract][Full Text] [Related]
18. Differential role of the NLRP3 inflammasome in infection and tumorigenesis.
Tartey S; Kanneganti TD
Immunology; 2019 Apr; 156(4):329-338. PubMed ID: 30666624
[TBL] [Abstract][Full Text] [Related]
19. The NLRP3 Inflammasome as a Pharmacological Target.
Marchetti C
J Cardiovasc Pharmacol; 2019 Oct; 74(4):285-296. PubMed ID: 31335445
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular pathobiology of inflammasomes: inflammatory machinery and beyond.
Li PL
Antioxid Redox Signal; 2015 May; 22(13):1079-83. PubMed ID: 25779752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
